<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/6083E7FB-0220-4F5F-97B0-7F6113B49A0C"><gtr:id>6083E7FB-0220-4F5F-97B0-7F6113B49A0C</gtr:id><gtr:name>MRC Unit, The Gambia</gtr:name><gtr:address><gtr:line1>MRC Laboratories, The Gambia</gtr:line1><gtr:line2>Atlantic Road PO Box 273</gtr:line2><gtr:line4>Fajara</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Gambia</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6083E7FB-0220-4F5F-97B0-7F6113B49A0C"><gtr:id>6083E7FB-0220-4F5F-97B0-7F6113B49A0C</gtr:id><gtr:name>MRC Unit, The Gambia</gtr:name><gtr:address><gtr:line1>MRC Laboratories, The Gambia</gtr:line1><gtr:line2>Atlantic Road PO Box 273</gtr:line2><gtr:line4>Fajara</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Gambia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/13569EF5-7C82-4648-9E00-EBA5A579BF8C"><gtr:id>13569EF5-7C82-4648-9E00-EBA5A579BF8C</gtr:id><gtr:firstName>Maimuna</gtr:firstName><gtr:surname>Mendy</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U190071516"><gtr:id>650E3A3F-8A32-411F-B2ED-0DEAA88B15FA</gtr:id><gtr:title>Long term vaccine efficacy of hepatitis B vaccination of Keneba - Manduar residents</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U190071516</gtr:grantReference><gtr:abstractText>A long standing cohort of children vaccinated against hepatitis (HBV) has been followed up to determine the duration of protective proteins (antibody) responses induced by infant vaccination, and to determine vaccine efficacy against infection and against carriage. Another survey round to study long term efficacy of HBV vaccination is now due. Concurrently carriers of HBV have also been regularly followed up. Primary aims of this study are: 1) to assess vaccine efficacy 2) to assess the persistence of vaccine induced antibody levels related to time since vaccination and to peak antibody levels; 3) to explore the spatial relationship between the pressure of infection in a household (by assessing duration of residence with a chronic carrier) and clustering of break through infection; and 4) to explore the genetic determinants of immune responses in relation to antibody responses and to breakthrough infection.</gtr:abstractText><gtr:technicalSummary>Baseline surveys of Hepatitis B virus (HBV) infection among the population of Keneba, Manduar and Kantong Kunda were completed in 1974, 1980 and 1984. In 1984, all non-immune children under the age of 5 years were vaccinated against HBV, and since then all children born in the villages have been vaccinated and their data entered into a database, which now contains details on over 2000 individuals. This long standing cohort of HBV vaccinated children has since been followed up in 1989, 1993, and 1998 to determine the duration of protective antibody responses induced by infant vaccination, and to determine vaccine efficacy against infection and against carriage. Another survey round to study long term efficacy of HBV vaccination is now due. Concurrently carriers of HBV have also been regularly followed up. Primary aims of this study are: 1) to assess vaccine efficacy against break through infection (anti-Bc present) and against chronic carriage; 2) to assess the persistence of vaccine induced antibody levels (anti-HBs) related to time since vaccination and to peak antibody levels; 3) to explore the spatial relationship between the pressure of infection in a household (by assessing duration of residence with a chronic carrier) and clustering of break through infection; and 4) to explore the genetic determinants of immune responses in relation to antibody responses and to breakthrough infection.</gtr:technicalSummary><gtr:fund><gtr:end>2011-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2000-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>1389328</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>London School of Hygiene and Tropical Medicine (LSHTM)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Faculty of Epidemiology and Population Health</gtr:department><gtr:description>LSHTM</gtr:description><gtr:id>D657F9BC-335E-4822-9F89-A57D5BFD9219</gtr:id><gtr:impact>Generate DNA, now kept in archive Generate host genetic data from vaccinated individuals.</gtr:impact><gtr:outcomeId>C17BCEE9F46-1</gtr:outcomeId><gtr:partnerContribution>The laboartory experiments for the host genetics studies were conducted by the collaboratorSupervision</gtr:partnerContribution><gtr:piContribution>Conduct epidemiology study, and sero survey on HBV infection and vaccine efficcacy study in Keneba and Manduar</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>London School of Hygiene and Tropical Medicine (LSHTM)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Faculty of Epidemiology and Population Health</gtr:department><gtr:description>LSHTM</gtr:description><gtr:id>FB986110-44A4-4D7C-BCE1-9F7BCFF7D757</gtr:id><gtr:impact>Generate DNA, now kept in archive Generate host genetic data from vaccinated individuals.</gtr:impact><gtr:outcomeId>C17BCEE9F46-2</gtr:outcomeId><gtr:partnerContribution>The laboartory experiments for the host genetics studies were conducted by the collaboratorSupervision</gtr:partnerContribution><gtr:piContribution>Conduct epidemiology study, and sero survey on HBV infection and vaccine efficcacy study in Keneba and Manduar</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>degaule Foundation</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>CB511E4B-FE0C-4B43-AFFE-543FFEB3E5C0</gtr:id><gtr:impact>Gave a talk to diners at a fund raising dinner

Improved awareness of the audience</gtr:impact><gtr:outcomeId>76C8CD06061</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>A simple PCR based assay was developed to measure HBV DNA in serum of HBV chronic carriers.</gtr:description><gtr:id>CFEDC9A3-570E-4C24-8D8B-F2D4CADAEA8D</gtr:id><gtr:impact>This has enabled us to perform many of HBV DNA assays at much lower cost compared to commercially available tests. The tool has been used to study the natural history of HBV chronic infection and for monitoring patients on ARV.</gtr:impact><gtr:outcomeId>A56F95E9818</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>qPCR assay for HBV DNA quantification</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2007</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>An access data base was developed to capture data from ELISA plate readers of HBV serology results. This then removed the data entry step and thus remove transcription error.</gtr:description><gtr:id>BD92DCBF-830C-43D1-8675-7A575B1976F3</gtr:id><gtr:impact>Data entry is faster and the time between laboratory tests are performed to when they are acvailable for analysis is shortened significantly.</gtr:impact><gtr:outcomeId>CF376645D94</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Access programe for capturing of HBV serology data</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type><gtr:yearFirstProvided>2007</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>51EC302C-E1F0-4D0F-B592-8C5000F5E1C1</gtr:id><gtr:title>Seasonal variation in TP53 R249S-mutated serum DNA with aflatoxin exposure and hepatitis B virus infection.</gtr:title><gtr:parentPublicationTitle>Environmental health perspectives</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/58a6b10f0a0cde8aabf630942fff70f1"><gtr:id>58a6b10f0a0cde8aabf630942fff70f1</gtr:id><gtr:otherNames>Villar S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0091-6765</gtr:issn><gtr:outcomeId>pm_15177_27_21768053</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2C9F8A24-B851-4BD1-9967-1C487FF104C8</gtr:id><gtr:title>Observational study of vaccine efficacy 24 years after the start of hepatitis B vaccination in two Gambian villages: no need for a booster dose.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0cc8502cee018caa2dfd8752dd14a92d"><gtr:id>0cc8502cee018caa2dfd8752dd14a92d</gtr:id><gtr:otherNames>Mendy M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_15177_27_23533578</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9FB4AA69-BB64-4AC3-81AA-7C537A47582D</gtr:id><gtr:title>Changes in viral load and HBsAg and HBeAg status with age in HBV chronic carriers in The Gambia.</gtr:title><gtr:parentPublicationTitle>Virology journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e4312437420f8d76a925048cdb000f56"><gtr:id>e4312437420f8d76a925048cdb000f56</gtr:id><gtr:otherNames>Mendy ME</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1743-422X</gtr:issn><gtr:outcomeId>123188D5DA2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2949F48E-A774-41F3-BF97-03A189F80EEF</gtr:id><gtr:title>Long-term protection against carriage of hepatitis B virus after infant vaccination.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8adf13cea6bd0d317f7b78f78d9b9906"><gtr:id>8adf13cea6bd0d317f7b78f78d9b9906</gtr:id><gtr:otherNames>van der Sande MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>E5059A050BC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>619D1E38-59FE-419D-970D-95DFC67CBF9F</gtr:id><gtr:title>Host genetic factors and vaccine-induced immunity to HBV infection: haplotype analysis.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c80680588121abbe1c39857e8f456038"><gtr:id>c80680588121abbe1c39857e8f456038</gtr:id><gtr:otherNames>Ryckman KK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>Fpxy1CwX5R7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A7F7B110-A335-49E5-A6A0-396A28D61451</gtr:id><gtr:title>Host genetic factors and vaccine-induced immunity to hepatitis B virus infection.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b57f3faab5ebc7c5cb4b1e9f15656da1"><gtr:id>b57f3faab5ebc7c5cb4b1e9f15656da1</gtr:id><gtr:otherNames>Hennig BJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5FD9AF73BC2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F0A221D6-BA64-4705-A03E-441DE002E8CB</gtr:id><gtr:title>Application of real-time PCR to quantify hepatitis B virus DNA in chronic carriers in The Gambia.</gtr:title><gtr:parentPublicationTitle>Virology journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e4312437420f8d76a925048cdb000f56"><gtr:id>e4312437420f8d76a925048cdb000f56</gtr:id><gtr:otherNames>Mendy ME</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1743-422X</gtr:issn><gtr:outcomeId>D45BF57C664</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U190071516</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>D8F3A27D-084A-40BB-A046-087DACE23410</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>3.4  Vaccines</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>